CRISPR Therapeutics 1 article

Programmable genome modification is central to CRISPR Therapeutics, a genome-editing biotechnology company associated with CRISPR gene editing and Cas9 genome editing. The platform further combines ex vivo hematopoietic stem cell editing with hemoglobinopathy gene editing, with sickle cell disease genetic medicine defining an important delivery, nuclease, cell-processing or disease-specific aspect of the editing strategy. GenoMethods separates genome-editing methods from the corporate entity and from individual genetic medicines; the editing profile of CRISPR Therapeutics also includes beta thalassemia genetic medicine.